The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression

Molecular Cancer Therapeutics

Volumn 13, Issue 12, 2014, Pages 3074-3085

  Kim, Jeong Min ^a   Jeung, Hei Cheul ^a   Rha, Sun Young ^a   Yu, Eun Jeong ^a,b   Kim, Tae Soo ^a   Shin, You Keun ^a   Zhang, Xianglan ^a   Park, Kyu Hyun ^a   Park, Seung Woo ^a   Chung, Hyun Cheol ^a   Powis, Garth ^c  

^a Yonsei University College of Medicine   (South Korea)

^b BAYLOR UNIVERSITY   (United States)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM9 PROTEIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RAV 18; OXYGEN; PROTEINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ADAM9 PROTEIN, HUMAN; DISINTEGRIN; MEMBRANE PROTEIN; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CATALYSIS; CELL ADHESION; CELL HYPOXIA; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CANCER; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; ANOXIA; ANTAGONISTS AND INHIBITORS; CELL MOTION; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; STOMACH NEOPLASMS; TUMOR CELL LINE; TUMOR VOLUME; XENOGRAFT;

ADAM PROTEINS; ANIMALS; ANOXIA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DISINTEGRINS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HETEROGRAFTS; HUMANS; MEMBRANE PROTEINS; MICE; NEOPLASM INVASIVENESS; PROTEIN BINDING; RNA INTERFERENCE; STOMACH NEOPLASMS; TUMOR BURDEN;

EID: 84918506919     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-1001     Document Type: Article

References (26)

1. Albelda SM. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993;68:4-17.
2. Nicolson GL. Tumor and host molecules important in the organ preference of metastasis. Semin Cancer Biol 1991;2:143-54.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
4. Becherer JD, Blobel CP. Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol 2003;54:101-23.
5. Grützmann R, Lüttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I, et al. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 2004;90:1053-8.
6. Hirao T, Nanba D, Tanaka M, Ishiguro H, Kinugasa Y, Doki Y, et al. Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res 2006;312:331-9.
7. Lendeckel U, Kohl J, Arndt M, Carl McGrath S, Donat H, Röcken C. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 2005;131:41-8.
8. Yamada D, Ohuchida K, Mizumoto K, Ohhashi S, Yu J, Egami T, et al. Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer. Anticancer Res 2007;27:793-9.
9. Edwards DR, Handsley M, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008;29:258-89.
10. Fischer OM, Hart S, Gschwind A, Prenzel N, Ullrich A. Oxidative and osmotic stress signaling in tumor cells is mediated byADAMproteases and heparin-binding epidermal growth factor. Mol Cell Biol 2004;24:5172-83.
11. Sung SY, Kubo H, Shigemura K, Arnold RS, Logani S, Wang R, et al. Oxidative stress inducesADAM9protein expression in human prostate cancer cells. Cancer Res 2006;66:9519-26.
12. Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Rcken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 2005;26:17-24.
13. Cisse MA, Gandreuil C, Hernandez J, Martinez J, Checler F, Vincent B. Design and characterization of a novel cellular prion-derived quenched fluorimetric substrate of alpha-secretase. Biochem Biophys Res Commun 2006;347:254-60.
14. Roghani M, Becherer JD, Moss ML, Atherton RE, Erdjument-Bromage H, Arribas J, et al. Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. J Biol Chem 1999;274:3531-40.
15. Shigemura K, Sung SY, Kubo H, Arnold RS, Fujisawa M, Gotoh A, et al. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate 2007;67:722-31.
16. Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, Pierce A, et al. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin Proteomics 2011;8:9.
17. Canault M, Leroyer AS, Peiretti F, LesÃche G, Tedgui A, Bonardo B, et al. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol 2007;171:1713-23.
18. Reiss K, Cornelsen I, Husmann M, Gimpl G, Bhakdi S. Unsaturated fatty acids drive disintegrin and metalloproteinase (ADAM)-dependent cell adhesion, proliferation, and migration by modulating membrane fluidity. J Biol Chem 2011;286:26931-42.
19. Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR, et al. Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res 2011;71:7433-41.
20. Guo J, He L, Yuan P, Wang P, Lu Y, Tong F, et al. ADAM10 overexpression in human non-small cell lung cancer correlates with cell migration and invasion through the activation of the Notch1 signaling pathway. Oncol Rep 2012;28:1709-18.
21. Shou Z, Jin X, Zhao Z. Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer. Ann Surg 2012; 256:1014-22.
22. Miyazaki Y, Shinomura Y, Tsutsui S, Zushi S, Higashimoto Y, Kanayama S, et al. Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor. Gastroenterology 1999;116:78-89.
23. Park JW, Baek NS, Lee SC, Oh SJ, Jang SH, Kim IH, et al. Preclinical efficacy testing for stomach and liver cancers. Cancer Res Treat 2014;46:186-93.
24. Izumi Y, Hirata M, Hasuwa H, Iwamoto R, Umata T, Miyado K, et al. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 1998;17:7260-72.
25. Schfer B, Gschwind A, Ullrich A. Multiple G-protein -coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 2004;23:991-9.
26. Stupack DG. The biology of integrins. Oncology 2007;21:6-12.